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Background: Insulin resistance is one of the hallmark manifestations of obesity and Type II diabetes and reversal of
this pathogenic abnormality is an attractive target for new therapies for Type II diabetes. A recent report that metformin,
a drug known to reverse insulin resistance, demonstrated in vitro the metformin can inhibit AMP deaminase (AMPD)
activity. Skeletal muscle is one of the primary organs contributing to insulin resistance and that the AMPD1 gene is
selectively expressed at high levels in skeletal muscle.
Methods: Recognizing the background above, we asked if genetic disruption of the AMPD1 gene might ameliorate the
manifestations of insulin resistance. AMPD1 deficient homozygous mice and control mice fed normal chow diet or a
high-fat diet, and blood analysis, glucose tolerance test and insulin tolerance test were performed. Also, skeletal muscle
metabolism and gene expression including nucleotide levels and activation of AMP activated protein kinase (AMP kinase)
were evaluated in both conditions.
Results: Disruption of the AMPD1 gene leads to a less severe state of insulin resistance, improved glucose tolerance and
enhanced insulin clearance in mice fed a high fat diet. Given the central role of AMP kinase in insulin action, and its
response to changes in AMP concentrations in the cell, we examined the skeletal muscle of the AMPD1 deficient mice
and found that they have greater AMP kinase activity as evidenced by higher levels of phosphorylated AMP kinase.
Conclusions: Taken together these data suggest that AMPD may be a new drug target for the reversal of insulin
resistance and the treatment of Type II diabetes.
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Type II diabetes and the associated disorder referred to
as the metabolic syndrome affect more than 380 million
people in the world and the prevalence of these disor-
ders is predicted to increase in the future [1]. The
fundamental abnormality in glucose metabolism under-
lying these disorders is insulin resistance [2]. While insulin
resistance can be caused by a number of factors, there is a
large body of evidence that a high fat diet with resultant
fat accumulation in various organs is a major predisposing
factor to the development of insulin resistance [2]. One of* Correspondence: morisaki@ri.ncvc.go.jp
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setting of a high fat diet is skeletal muscle, and numer-
ous studies have documented that skeletal muscle which
is a major site of insulin action contributes to the state
of insulin resistance observed in animals and humans
consuming a high fat diet [3].
Given that skeletal muscle is one of the major organs
that contributes to insulin resistance it stands to reason
that therapies directed to targets expressed in this tissue
may offer novel approaches to treating these disorders.
A recent report demonstrated that AMP deaminase
(AMPD) isolated from skeletal muscle is inhibited by
metformin, one of the best known drugs for reversing
the pathologic state of insulin resistance [4]. While the
results of this study are intriguing it is difficult to assess
if inhibition of AMPD is the target responsible for the
in vivo effects of this drug on insulin action since manyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of numerous enzymatic activities [5].
To address the question of whether AMPD represents
a valid new target for drug development to reverse or
ameliorate insulin resistance we have taken the ap-
proach of gene disruption to test this hypothesis more
definitively. In particular we elected to reduce the level
of AMPD enzyme activity in skeletal muscle through
disruption of the AMPD1 gene, the predominant AMPD
gene expressed in skeletal muscle [6,7]. The results
described in this report demonstrate that mice rendered
deficient in AMPD1 enzyme activity have a milder state
of insulin resistance, improved glucose tolerance, and
enhanced insulin clearance when fed a high fat diet when




We previously described the generation of AMPD1
deficient mice [7]. Heterozygous AMPD1 deficient mice
(A1(+/−) mice) were backcrossed with C57BL/6 control
mice more than 10 times. Genotyping was performed
as described before [7]. Animals had free access to food
(CE-2, CLEAR) and water, and were housed in a con-
trolled SPF environment with a 12-h light–dark cycle
and constant temperature (25°C).
AMPD1 deficient homozygous mice (A1(−/−) mice)
and control mice (Wt mice) at 5 weeks old were fed normal
chow diet (CD: CE-2) or a high-fat diet (HFD: HFD32)
(CLEAR, Tokyo, Japan) with 60% fat calories for 12 weeks.
All animal experiments were approved by the Com-
mittee on Animal Research of National Cerebral and
Cardiovascular Center and were performed according to
the guidelines for the protection of experimental animals
of National Cerebral and Cardiovascular Center.
CT scan
The adiposity of mice was examined radiographically
using CT (LaTheta LCT-100, ALOKA) according to the
manufacturer’s protocol. Two-mm intervals were scanned
from the diaphragm to bottom of the abdominal cavity.
Blood analysis: insulin, FFA, triglyceride, cholesterol,
adiponectin and leptin
Samples were obtained from the mice fasted for 17 h.
Plasma insulin levels were measured using an ELISA kit
(Morinaga, Yokohama, Japan). Serum FFA, triglyceride,
cholesterol were detected by ACS-ACOD methods,
GPO-HDAOS methods and HDAOS methods. The
levels of leptin, adiponectin were measured using a
mouse leptin ELISA kit (Morinaga, Yokohama, Japan), a
mouse adiponectin ELISA kit (Ootuka, Tokyo, Japan),
respectively.Glucose and insulin tolerance
Groups of male mice before and after HFD were used
for intraperitoneal glucose injection. After a 17-hr fast,
plasma insulin and glucose levels were measured and
d-glucose (2 g/kg body weight) was administered.
Blood samples were taken from the tail vein at indi-
cated times. Blood glucose levels were detected at 15,
30, 60, 90, 120 min and blood glucose concentration
was determined using a glucometer.
Groups of male mice before and after HFD were used
for insulin tolerance tests. Mice were fasted for 5 h. Blood
glucose levels were detected at 0, 15, 30, 60, 90 min after
intraperitoneal injection 0.75 units insulin/kg body weight.Western blot analysis
Tissues were sonicated and homogenized in RIPA buffer
(1× PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, 100 μg/ml phenylmethylsulforyl fluoride,
45 μg/ml aprotinin, 100 mM sodium orthovanadate).
The supernatant of the homogenate was used for protein
determination with a BCA Protein Assay Kit (Pierce, IL,
USA) and electrophoresis. Samples were loaded on SDS-
PAGE gel with the same amount of total protein. Electro-
phoretic transfer to polyvinylidene difluoride membranes
was followed by immunoblotting with different primary
antibodies. Signals were developed with an ECL kit
(Amersham, Piscataway, USA).Results
Glucose and insulin dynamics
To test the basic premise of this study, i.e. does a loss of
AMPD activity alter insulin resistance, we examined
blood glucose and insulin levels in wild-type and A1
(−/−) mice fed a standard chow diet (CD) and a high fat
diet (HFD). As shown in Figure 1, after 12 weeks on a
HFD A1(−/−) mice had a significantly lower fasting
blood glucose than the wild-type mice and blood insulin
levels were significantly lower in the A1(−/−) mice on
the HFD in both the fasting state and 3 hours after
re-feeding. HOMA-IR analysis documented that insulin
resistance was reduced in the A1(−/−) mice relative to
the wild-type mice on the HFD.
Glucose and insulin dynamics were further assessed
with glucose and insulin tolerance tests in these mice
(Figure 2). Figure 2A demonstrates that blood glucose
levels were not appreciably different in the wild-type and
A1(−/−) mice on a standard chow diet after a glucose
challenge. In contrast, Figure 2B shows the A1(−/−)
mice maintained on a HFD had a more rapid return of
blood glucose levels to normal levels than did the wild
type animals following a glucose challenge. Figure 2C
and D illustrate the results of the insulin tolerance test in
these two groups of mice. The A1(−/−) mice maintained
Figure 1 Blood glucose and insulin levels. A. Blood glucose levels in mice fed with normal chow diet (CD) and after high fat diet (HFD)
challenge. B. Blood insulin levels in mice fed with CD and after HFD challenge. C. HOMA-IR index in mice fed with CD and after HFD challenge.
Wt: wild type mice, A1(−/−): AMPD1 deficient homozygote mice. *: significant difference between Wt and A1(−/−) mice.
Cheng et al. BMC Endocrine Disorders 2014, 14:96 Page 3 of 7
http://www.biomedcentral.com/1472-6823/14/96on a HFD had significantly lower blood glucose levels 30
and 60 min after insulin administration.
Prior studies have demonstrated insulin clearance is
reduced in obese, hyperinsulinemic human subjects [8],
and a recent study has indicated insulin clearance is asso-
ciated with AMPD1 haplotype in man [9]. To assess insu-
lin clearance in the A1(−/−) animals we determined
insulin levels relative to insulin production as measuredFigure 2 Glucose tolerance test and insulin tolerance test. A. Glucose tol
test in mice after high fat diet (HFD) challenge. C. Insulin tolerance test in mic
with normal chow diet (CD). Wt: wild type mice, A1(−/−): AMPD1 deficient hoby C-peptide levels. As shown in Figure 3, the ratio of
C-peptide/insulin was significantly reduced in both groups
of animals on a HFD, though the reduction in the ratio was
significantly lower in the A1(−/−) mice than in Wt mice.
Body weight and adiposity
Both wild-type and A1(−/−) mice gained weight on the
HFD relative to the cohorts fed CD but there was noerance test in mice fed with normal chow diet (CD). B. Glucose tolerance
e fed with normal chow diet (CD). D. Insulin tolerance test in mice fed
mozygote mice. *: significant difference between Wt and A1(−/−) mice.
Figure 3 Insulin production. A. C-peptide levels in mice fed with normal chow diet (CD) and after high fat diet (HFD) challenge. B. C-peptide/
Insulin ratios in mice fed with normal chow diet (CD) and after high fat diet (HFD) challenge. Wt: wild type mice, A1(−/−): AMPD1 deficient
homozygote mice. *: significant difference between Wt and A1(−/−) mice.
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Wt and A1(−/−) mice on a HFD (Figure 4A). Food
consumption was comparable in the two groups of mice
on a HFD (Figure 4B). Total body fat was assessed by CT
scans, and while both groups of mice accumulated more
fat on the HFD relative to those on the standard CD, con-
sistent with the greater rate of weight gain on the HFD,
there was no detectable difference in total body fat relative
to total body weight in the A1(−/−) mice compared to Wt
mice (Figure 4C and D). Because of the central role skel-
etal muscle plays in insulin resistance [3] and because
AMPD1 is predominately expressed in this tissue, fat
content of the skeletal muscle was assessed. As with total
body fat, skeletal muscle fat increased in both groups of
mice while on the HFD (data not shown) but there was no
obvious difference between the A1(−/−) and wild-type
mice on HFD (Additional file 1: Figure S1).Figure 4 Body weight and fat accumulation change after high fat die
with normal chow diet, A1(−/−)-CD: AMPD1 deficient homozygote mice fe
A(−/−)-HFD: AMPD1 deficient homozygote mice after HFD challenge. B. Fo
the CT scan exam. Wt: wild type mice, A(−/−): AMPD1 deficient homozygoBlood lipids and lipid-related hormones were quanti-
tated in both groups of mice on both the CD (data not
shown) and the HFD (Table 1). None of these parame-
ters of lipid metabolism was appreciably different be-
tween the A1(−/−) and wild-type mice on either diet.
Skeletal muscle metabolism and gene expression
Gastrocnemius muscle of sedentary animals was ana-
lyzed for purine metabolites in A1(−/−) and Wt mice on
a HFD (Table 2) (ATP, ADP, AMP, IMP, adenosine and
cAMP). ATP, ADP, AMP, adenosine, and cAMP levels
were not detectably different in skeletal muscle of the
two groups of mice. However, IMP was undetectable in
the skeletal muscle of A1(−/−) mice in contrast to the
easily detectable levels in Wt mice.
A potential consequence of loss of AMPD activity in
skeletal muscle, and a potential explanation for thet (HFD) challenge. A. Body weight change. Wt-CD: wild type mice fed
d with normal chow diet, Wt-HFD: wild type mice after HFD challenge,
od intake during HFD challenge. C. CT scan. D. Fat ratio calculated by
te mice.
Table 1 The parameters of lipid metabolism in blood
Wt A1(−/−)
TG (mg/dl) 41 ± 8 42 ± 3
FFA (mEq/L) 512 ± 95 473 ± 63
TC (mg/dl) 271 ± 11 240 ± 22
Leptin (ng/ml) 50 ± 4 43 ± 3
Adiponectin (mg/L) 15 ± 4 15 ± 5
n = 5.
Wt: control mice; A1(−/−): AMPD1 deficient homozygous mice. Fasting for
17 hrs after 12 weeks HFD challenge. TG: triglyceride, FFA: free fatty acid,
TC: total cholesterol.
Figure 5Western blot study for phosphorylation of AMPK and
ACC. Phosphorylation of AMPK and ACC in skeletal muscles. Antibody
for phosphorylated AMPK, AMPK, ACC, or phosphorylated ACC was
used. P-AMPKα (Thr172): phosphorylated AMPK at Thr172, AMPK: total
AMPK. P-ACC (Ser79): phosphorylated ACC at Ser79. ACC: total ACC. Wt:
wild type mice, A(−/−): AMPD1 deficient homozygote mice. CD: fed
with normal chow diet, HFD: after high fat diet challenge.
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tial activation of AMP activated protein kinase (AMPK) in
the A1(−/−) mice. As shown in Figure 5, phosphorylation
of AMPK was greater in gastrocnemius muscle of A1(−/−)
than in Wt animals fed the standard CD. Upon HFD chal-
lenge, we observed an even greater increase in phosphor-
ylation of AMPK in gastrocnemius muscle of A1(−/−)
compared with Wt animals. Also, acetyl-CoA carboxylase
(ACC) was similarly phosphorylated in A1(−/−) mice and
this change was prominent after HFD challenge.
Expression of a number of genes has been associated
with changes in insulin sensitivity [10]. A limited survey
of these genes, as judged by mRNA levels, revealed no
significant differences in expression of any of these genes
with one exception (Figure 6). Leptin receptor mRNA
was about 50% more abundant in skeletal muscle of the
A1(−/−) mice.
Discussion
The results of this study demonstrate that disruption of
the AMPD1 gene with reduction of AMPD activity in
skeletal muscle protects mice from a number of the
adverse metabolic consequences of a high fat diet. The
following indices of glucose metabolism are significantly
improved in A1(−/−) mice on a high fat diet: fasting
blood glucose is lower, fasting and post-prandial insulin
levels are lower, glucose and insulin tolerance tests are
improved, and insulin resistance is less pronounced in
the A1(−/−) animals. In addition to these measures of
insulin action A1(−/−) animals exhibited a higher rate ofTable 2 Nucleotides, adenosine and cAMP in skeletal
muscles
Wt A1(−/−)
ATP (nmol/mg) 10.00 ± 0.25 9.90 ± 0.28
ADP (nmol/mg) 2.79 ± 0.13 2.78 ± 0.13
AMP (nmol/mg) 0.36 ± 0.01 0.40 ± 0.03
IMP (nmol/mg) 0.26 ± 0.04 not detected
Adenosine (pmol/mg) 9.54 ± 0.71 9.86 ± 0.44
cAMP (pmol/mg) 1.00 ± 0.10 0.99 ± 0.09
mean ± SE (nmol or pmol/mg wet weight), n = 5.insulin clearance on a high fat diet. While insulin clear-
ance is determined by many factors including renal
excretion it is also influenced by insulin uptake by per-
ipheral organs such as skeletal muscle [3].
These studies do not indicate which organ(s) are re-
sponsible for these various measures of enhanced insulin
action but given the central importance of skeletal muscle
in contributing to the state of insulin resistance in animals
and humans on a high fat diet [3,11] and recognizing that
AMPD1 is only highly expressed in skeletal muscle of
humans and rodents [6], it points to changes in skeletal
muscle metabolism as the most likely tissue to produce
the observed changes in insulin and glucose metabolism
in the whole animal.
As expected, fat content of skeletal muscle increased
in mice on a high fat diet, as did fat content in other
tissues. But there were no demonstrable differences in
fat content of skeletal muscle, or fat content of other
tissues, in the A1(−/−) animals, suggesting that the
mechanism for enhanced insulin sensitivity is not the
result of reduced levels of fat in skeletal muscle or other
organs. Consistent with these findings A1(−/−) mice
exhibited a comparable increment in weight gain result-
ant from the high fat diet.
Many interventions and drugs have been reported to
improve insulin sensitivity through affecting the activity
Figure 6 mRNA expression of various molecules after high fat diet challenge. Insulin-R: insulin receptor, Lept-R : reptin receptor,
Pgk1:phosphoglyceratekinase 1, Gck: glucokinase, Ascl: acyl-CoA synthetase, A1R: adenosine type 1 receptor. Wt: wild type mice, A(−/−): AMPD1
deficient homozygote mice. CD: fed with normal chow diet, HFD: after high fat diet challenge. *: significant difference between Wt and A1(−/−) mice.
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resultant alternations in adenine nucleotide metabolism
might be expected to lead to activation AMP kinase
which is known to be regulated by adenine nucleotides
[5]. Consistent with this hypothesis we observed an
increase in the levels of phosphorylated AMP kinase in
skeletal muscle of A1(−/−) mice. In sedentary animals
we did not detect any changes in the total concentration
of AMP or any other adenine nucleotides but we were
not able to quantitate the levels of free AMP, the most
critical effector of AMP kinase activation, and we postu-
late that the small fraction of total AMP that is in the
pool of free AMP may have been increased leading
to the activation of AMP kinase. This conclusion is
supported by the failure to detect any IMP, a product of
the AMPD reaction, in the skeletal muscle of the A1
(−/−) animals.
An unexpected and potentially interesting finding with
regard to the phenotypic changes observed in AMPD
deficient mice is the increase in expression of the leptin
receptor in the skeletal muscle of these animals. Leptin
is known to increase the amount phosphorylated AMP
kinase in skeletal muscle [12] and it is possible that
enhanced activity of the leptin pathway may also have
contributed to the observed increase in phosphorylated
AMP kinase in the skeletal muscle of the A1(−/−) mice.
How alterations in AMPD activity affect expression of
the leptin receptor remain to be determined but this ob-
servation suggests that alterations in AMPD activity may
lead to changes in other pathways that affect insulin and
glucose metabolism in myocytes. In this regards, the
crossing A1(−/−) mice with db/db mice will provide the
further evidence for the interaction between AMPD
activity and the leptin receptor.
Decreased levels of IMP in skeletal muscles in A1(−/−)
mice indicated that other AMPD genes were not upreg-
ulated in muscles. In fact, total AMPD activity was quite
low in muscles of A1(−/−) mice as reported before [7].
Therefore, skeletal muscles in A1(−/−) mice should have
striking difference in metabolic conditions if there wereany change of endogenous AMPD1 at baseline and after
12-week HFD in Wt mice. Also, besides the skeletal
muscle, liver, adipose tissue, and others have an import-
ant role in regulating glucose metabolism at baseline
and after HFD challenge. However, we found that no
difference of AMPD2 mRNA expression was observed
in liver between Wt and A1(−/−) mice at base line or
after HFD challenge (Additional file 2: Figure S2), while
AMPD2 mRNA expression was slightly increased in liver
of both mice after HFD. Therefore, we thought that the
AMPK activity at baseline or after HFD challenge in
other organs was not appreciably affected by AMPD1
deficiency.
Regarding AMPK activation in A1(−/−) mice, it could
be possible that other metabolites including IMP, hypo-
xanthine, or uric acid in the pathway downstream to
AMPD might play a role for it. Further investigation will
be awaited for delineation of precise mechanisms for
AMPK activation in AMPD1 deficiency.
During the revision of this report, other reports indi-
cated that AMPD1 deficient mice showed only moderate
increase in AMPK activation despite increase in AMP
levels and AMP/ATP ratio and that there were no favor-
able metabolic phenotype in AMPD1 deficient mice after
HFD challenge [13,14]. We think that different protocol
for HFD challenge created different results and that
further study is awaited for delineating the importance
of AMPD1 on insulin metabolism.
Conclusions
In conclusion, the results of this study validate AMP
deaminase as potential new drug target for the amelior-
ation of insulin resistance, which is one of the under-
lying causes of the metabolic syndrome and Type II
diabetes. The results indicate that inhibition of AMPD
may lead to improved insulin dynamics in the resting
state and without the requirement of concomitant weight
loss or reduction in fat content of skeletal muscle. While
the mechanism(s) by which reductions in AMPD activity
lead to this beneficial metabolic profile need more study
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a known pathway for decreasing insulin resistance, and
potentially a novel mechanism of action that may involve
the leptin receptor. The effects of reduced AMPD activity
in altering insulin action may not be unique to the mouse
as two studies have reported that AMPD1 deficient
human subjects have a lower incidence of type II diabetes
[15,16], an intriguing result that needs to be confirmed in
a larger group of individuals, and the demonstration that
AMPD1 haplotype is associated with changes in insulin
clearance in man [9]. AMPD1 deficiency is one of the
most common inherited defects in the Caucasian popula-
tion, with approximately 2% of individuals in this ethnic
group being homozygous for this gene defect, and few if
any of these individuals experience any adverse effects
from this enzyme deficiency [6] suggesting that not only
would inhibition of AMPD have beneficial effects in pa-
tients with the metabolic syndrome and diabetes but in-
hibition of this enzyme may lead to few deleterious effects.
Additional files
Additional file 1: Figure S1. Sudan Black staining of skeletal muscles.
Wt: wild type mice, A(−/−): AMPD1 deficient homozygote mice.
Additional file 2: Figure S2. AMPD2 mRNA expression after high fat
diet challenge. Wt: wild type mice, A(−/−): AMPD1 deficient homozygote
mice. CD: fed with normal chow diet, HFD: after high fat diet challenge.
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